JP2005530732A5 - - Google Patents

Download PDF

Info

Publication number
JP2005530732A5
JP2005530732A5 JP2003584094A JP2003584094A JP2005530732A5 JP 2005530732 A5 JP2005530732 A5 JP 2005530732A5 JP 2003584094 A JP2003584094 A JP 2003584094A JP 2003584094 A JP2003584094 A JP 2003584094A JP 2005530732 A5 JP2005530732 A5 JP 2005530732A5
Authority
JP
Japan
Prior art keywords
glp
pharmaceutical composition
composition according
compound
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003584094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/008457 external-priority patent/WO2003087139A2/en
Publication of JP2005530732A publication Critical patent/JP2005530732A/ja
Publication of JP2005530732A5 publication Critical patent/JP2005530732A5/ja
Pending legal-status Critical Current

Links

JP2003584094A 2002-04-10 2003-03-27 胃不全麻痺の治療 Pending JP2005530732A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (2)

Publication Number Publication Date
JP2005530732A JP2005530732A (ja) 2005-10-13
JP2005530732A5 true JP2005530732A5 (https=) 2006-05-18

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003584094A Pending JP2005530732A (ja) 2002-04-10 2003-03-27 胃不全麻痺の治療

Country Status (18)

Country Link
US (1) US20050164925A1 (https=)
EP (1) EP1496924A4 (https=)
JP (1) JP2005530732A (https=)
KR (1) KR20040098063A (https=)
CN (1) CN1735423A (https=)
AU (1) AU2003220403A1 (https=)
BR (1) BR0308904A (https=)
CA (1) CA2480858A1 (https=)
EA (1) EA200401345A1 (https=)
EC (1) ECSP045345A (https=)
HR (1) HRP20040939A2 (https=)
IL (1) IL164266A0 (https=)
MX (1) MXPA04009929A (https=)
NO (1) NO20044815L (https=)
NZ (1) NZ535684A (https=)
PL (1) PL373658A1 (https=)
WO (1) WO2003087139A2 (https=)
ZA (1) ZA200408111B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
CN1856338B (zh) 2003-07-21 2012-11-14 超治疗有限公司 用于治疗疾病和控制血糖的胃肠方法和装置
BR122019021416A2 (https=) * 2003-09-19 2019-12-21
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US8612016B2 (en) 2004-08-18 2013-12-17 Metacure Limited Monitoring, analysis, and regulation of eating habits
EP1868679B1 (en) 2005-02-17 2017-05-03 MetaCure Limited Non-immediate effects of therapy
WO2006087712A2 (en) 2005-02-17 2006-08-24 Metacure N.V. Charger with data transfer capabilities
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
EP1861160B1 (en) * 2005-03-24 2011-11-16 Metacure Limited Wireless leads for gastrointestinal tract applications
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
EP1890763A4 (en) 2005-06-02 2017-05-03 Metacure Limited Gi lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
JP2009534423A (ja) * 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Glp−1化合物
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
EP2150308B1 (en) * 2007-05-09 2018-08-08 MetaCure Limited Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US8642548B2 (en) * 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
MX2012012383A (es) 2010-04-30 2012-11-30 Sanwa Kagaku Kenkyusho Co Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Similar Documents

Publication Publication Date Title
JP2005530732A5 (https=)
US20240376175A1 (en) Novel GLP-1 Analogues
KR102906485B1 (ko) 변형된 gip 펩티드 유사체
JP2007001987A5 (https=)
ES2444622T3 (es) Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido N-terminal
CN102711804B (zh) 包含glp-1激动剂和甲硫氨酸的药物组合物
JP2002526454A5 (https=)
JP2007523881A5 (https=)
PT1143989E (pt) Exendinas para supressão de glucagon
CN108271356A (zh) 肠降血糖素-胰岛素缀合物
RU2007134156A (ru) Ацилированные glp-1 соединения
TWI353250B (en) Glp-1 pharmaceutical compositions
JP2011526886A5 (https=)
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
JP2018500291A (ja) 制御放出および持続的放出のためのelp融合タンパク質
JP2022543826A5 (https=)
AU2022222674A1 (en) Glucagon-like peptide-1 receptor antagonists
WO2015180634A1 (zh) 用于治疗2型糖尿病的长效肠激素多肽类似物及应用
US20240058422A1 (en) Glucagon-like peptide-1 receptor antagonists
HK40117578A (zh) 胰高血糖素样肽-1受体拮抗剂
RU2008129731A (ru) Новые пептиды-т-хелперные антигенные детерминанты (thd)
HK1207088B (zh) N-末端氨基酸经修饰的促胰岛素释放肽衍生物